Clinical trials: Multiple Sclerosis - Relapsing Remitting
Relapsing-Remitting Multiple Sclerosis
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study to investigate whether baseline treatment with high-dose interferon beta 1a (Rebif 44 μg x 3 ), administered at a high frequency, leads to…
- Trial name
- RETURN (NCT01142518)
- Testing
- Interferon beta 1a
- Volunteers
- 86 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis
The aim of this observational study is to compare Dimethyl fumarate (DMF) and Teriflunomide on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from French Observatory of Multiple…
- Trial name
- COMP-RMS (NCT03302442)
- Testing
- Non interventional study
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Nantes University Hospital
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS.
- Trial name
- NCT03870763
- Testing
- Dimethyl Fumarate, Peginterferon Beta-1a
- Where
- 23 sites in United States, Colombia and 11 more
- Volunteers
- 11 people
- Sponsor
- Biogen